Skip to content
Biodatica
Start free

Valo Therapeutics Oy

Frankfurt

OncologyPhase I
Compare Sign in to watch

What changed

Phase I trial registered: START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

2mo agoTrial registeredMay 12, 2026Source filing (opens the source filing in a new tab)

Momentum

67no change

Momentum 67 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase I

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Feb 2, 2023

    Melanoma (Skin), Triple-Negative Breast Cancer, Non-Small Cell Lung Cancer, Synovial Sarcoma, Myxoid Liposarcoma, Colorectal Cancer, Osteosarcoma, Sarcoma · RECRUITING · sponsor: Valo Therapeutics Oy · START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

    ClinicalTrials.gov · NCT05492682 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources